Actively Recruiting
A Pilot Feasibility and Acceptability Study of Remote ExerciSe Training mOdalities (PRESTO)
Led by NYU Langone Health · Updated on 2026-03-05
30
Participants Needed
1
Research Sites
138 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will investigate the acceptability and efficacy of 12 weeks of: Smart-device app-based (MyZone) Asynchronous Virtual, Synchronous Virtual, and in-person aerobic training in individuals at risk for Cardiovascular Disease (CVD) who do are not meeting American Heart Association (AHA) guidelines for physical activity. The study aims to 1) Assess the effect of several approaches to remote aerobic training on measures of physical activity, cardiovascular fitness and CVD risk, and 2) Quantitatively and qualitatively evaluate exercise training program fidelity, implementation, effectiveness, and remaining barriers to acceptance. Participants will be asked to undergo Cardiopulmonary Exercise Testing (CPET) before and after 12-weeks of training via one of the 4 modalities (random assignment) listed above. They will respond to questions regarding acceptability of the interventions.
CONDITIONS
Official Title
A Pilot Feasibility and Acceptability Study of Remote ExerciSe Training mOdalities (PRESTO)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 45 years
- At risk for cardiovascular disease with one or more of the following: hypertension, hyperlipidemia, Type 2 Diabetes Mellitus, smoking, obesity, or family history of premature cardiovascular disease
- Not meeting American Heart Association physical activity guidelines for at least 3 months prior to screening
- Hypertension defined as systolic blood pressure 140 mm Hg and/or diastolic blood pressure 90 mm Hg or use of anti-hypertensive medication
- Hyperlipidemia defined as LDL cholesterol 160 mg/dL and/or HDL cholesterol less than 50 mg/dL for women, less than 40 mg/dL for men, and fasting triglycerides greater than 150 mg/dL
- Diabetes Mellitus defined as hemoglobin A1c 6.5%, fasting glucose 126 mg/dL, 2-hour glucose 200 mg/dL after oral glucose tolerance test, or use of diabetes medication
- Current regular tobacco use
- Obesity defined as BMI 30 kg/m8
You will not qualify if you...
- Established diagnosis of atherosclerotic cardiovascular disease
- Any serious medical condition that would make exercise unsafe according to American College of Sports Medicine and American Heart Association guidelines
- Pregnant or planning pregnancy
- Planning to be away for more than 2 weeks during the intervention period
- Any biopsychosocial factors that may interfere with study participation as determined by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
Research Team
S
Sean Heffron, MD
CONTACT
R
Ryan Burnett
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here